Please assess the completion status of the following clinical trial:

Trial Title: Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed acute lymphoblastic leukemia or acute mixed lineage leukemia~  * Positive for Bcr-Abl fusion transcript (Philadelphia chromosome-positive disease) by RT-PCR~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Total bilirubin \< 2 mg/dL~* SGOT \< 3 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN (unless considered tumor-related)~* Creatinine \< 2.0 mg/dL ULN~* Serum amylase and lipase ≤ 1.5 times ULN~* Potassium, magnesium, and phosphorus normal (supplementation allowed)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No rare hereditary problems with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption~* No known sensitivity to any of the study drugs~* No severe medical condition that, in the opinion of the investigator, would preclude study participation~* No impaired cardiac function, including any of the following:~  * LVEF \< 45% or below the lower limit of normal by ECHO~ * Long QT syndrome or known family history of long QT syndrome~ * Clinically significant resting bradycardia (\< 50 beats per minute)~ * QTc \> 450 msec on baseline ECG (using the QTcF formula)~ * Myocardial infarction within the past 12 months~ * Other clinically significant heart disease, including any of the following:~    * Unstable angina~   * Congestive heart failure~   * Uncontrolled hypertension~   * Uncontrolled arrhythmias~* No other primary malignant disease requiring systemic treatment~* No acute or chronic liver, pancreatic, or severe renal disease~* No other severe and/or life-threatening medical disease~* No history of significant congenital or acquired bleeding disorder unrelated to cancer~* No impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug~* No history of non-compliance~PRIOR CONCURRENT THERAPY:~* More than 30 days since prior investigational agents~* No concurrent medications that have the potential to prolong the QTc interval~* No concurrent strong CYP3A4 inhibitors~* No concurrent therapeutic coumarin derivatives

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib+mVPD (Type: EXPERIMENTAL): Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan

Based on this trial design, predict the completion outcome and termination type (if applicable).